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thereby avoiding the complications induced 
by renal ischemia and surgical excision. 
However, only CA and RFA have encoun-
tered a widespread use: several case series 
reported short-to-intermediate-term results 
[1]. Therefore, if surgical and oncological 
IntroduCtIon
Renal cell carcinoma (RCC) accounts 
for 2-3% of adult malignancies [1] and the 
incidence has increased during the last 2 
decades, mostly because of the incidental 
detection of small, asymptomatic masses 
[2]. The management of localized renal cell 
carcinoma has evolved toward minimally in-
vasive and nephron-sparing surgery (NSS) 
[3]. With the increasing application of mini-
mally invasive surgery, ablative technologies 
have been investigated as an alternative. They 
include cryoablation (CA), radiofrequency 
ablation (RFA), microwave, high-intensity 
focused ultrasound, laser interstitial ther-
motherapy, microwave thermotherapy, and 
radiosurgery [4]. Tissue is destroyed in situ, 
Why we describe this case
Current guidelines suggest that treat-
ment with cryoablation can be an option 
for the treatment of small renal masses 
in selected patients. Here we report the 
case of a 54-year-old man with multiple 
renal lesions successfully undergone to 
cryoablation in one lesion
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Case report
Abstract
BACKGROUND: In the last decade, nephron-sparing surgery has largely supplanted the radical 
approach for the treatment of small renal masses. More recently, ablative technologies have been 
discussed as alternative in patients that are not eligible for surgical approach.
CASE SUMMARY: A 54-year-old Caucasian man was referred to our Urology Clinic for 
multiple renal masses. A computed tomography (CT) scan revealed three contrast-enhanced 
lesions located in the upper pole, middle renal, and in the lower pole of the left kidney 20 mm, 
25 mm, and 45 mm long, respectively. The patient underwent laparoscopic tumorectomy of 
two lesions and cryoablation of the left renal mass by the transperitoneal approach, performed 
without clamping the renal vessels. At the end of the procedure the operator posed a reno-ureteral 
ipsilateral stent to tutor the urinary tract. Tumor enucleation and cryoablation were chosen to 
preserve renal function.
CONCLUSION: This case report shows that in young patients with multiple renal tumors, 
cryoablation treatment is feasible and outcomes are promising as well. However, risk of 
complications should be considered and discussed with patients. 
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past medical history showed hypertension 
and hypercholesterolemia. He had no past 
surgical history. His renal functions and 
glomerular filtration rate were normal. Con-
trast-Enhanced Computed Tomography 
(CECT) revealed multi-focal hypodense 
renal masses and contrast enhancement. 
The features of the masses were suggestive 
of multiple renal cell carcinoma without dis-
semination (Figures 1 and 2).
Tumor masses were located in the upper 
pole, middle renal, and in the lower pole of 
the kidney. Pre-operative risk in our institu-
tion was defined using PADUA and RE-
NAL score. The lesion in the upper pole had 
a maximum diameter of 20 mm and had no 
communication with the urinary tract. 
PADUA score was 7p and RENAL score 
was 5a. The lesion located on the middle line 
had maximum diameter of 25 mm and was 
closed with the urinary tract, in fact PADUA 
score was 9a and RENAL score was 7a. The 
lower one had maximum diameter of 45 mm 
and reached urinary tract as well. Because of 
the size, it had PADUA score = 9a and RE-
NAL score = 10a. According to TMN clas-
sification, the patient was classified as T2b-
N0M0 clinical stage. The Charlson comor-
bidity score was 0.
The patient underwent laparoscopic trans-
peritoneal approach. After dissection of the 
perirenal fat, macroscopically the kidney 
showed a prominent area at the lower pole 
corresponding to the lesion. Identification 
of other tumor masses was performed by 
intra-abdominal ultrasonography. The pa-
tient underwent laparoscopic renal cryoab-
lation of the renal upper tumor and tumor 
enucleation of the middle renal and lower 
renal masses. At the end of the procedure, 
a double J reno-ureteral stent was posed. It 
was performed without clamping the renal 
vessels.
Postoperative laboratory examinations re-
sulted within normal values and renal func-
tion did not change. The stent was removed 
20 days after surgery. Histopathological ex-
aminations suggested a diagnosis of type 1 
papillary renal cell carcinoma and clear cell 
renal cell carcinoma. No adjuvant therapy 
following surgery was recommended.
2 months after ablative treatment, the pa-
tient was hospitalized due to the occurrence 
of hyperpyrexia. An abdominopelvic CT 
scan identified a leakage closed to middle 
renal space. The patient was treated by sys-
temic therapy including antibiotic therapy 
(grade II as Clavien-Dindo Classification 
Figure 1. Intravenous 
contrast abdominal 
computed tomography 
showing a contrast-
enhancing 45 mm-
diameter solid lesion 
(red arrow) in the left 
kidney.
Figure 2. Intravenous 
contrast abdominal 
computed tomography 
showing two contrast-
enhancing solid lesions 
20 mm in diameter (red 
arrow – the upper one) 
and 25 mm in diameter 
(red arrow – the lower) 
in the left kidney.
outcomes support the feasibility and efficacy 
of laparoscopic cryoablation (LRC) for re-
nal tumors, and safety can be maintained 
during the surgical procedure, this method 
may provide an alternative nephron-sparing 
surgery for selected patients [1]. Recently, 
Nielsen et al. in a large multi-institutional 
study reported satisfactory intermediate-
term oncological outcomes for small renal 
masses (SRMs). Unfortunately, no random-
ized controlled trials comparing nephron-
sparing surgery and cryoablation has been 
undertaken.
CAse report
A 54-year-old Caucasian man was admit-
ted to our Urology Clinic due to incidentally 
detected renal masses on the left side. His 
19
©SEEd Tutti i diritti riservati
Clinical  Management  Issues   2017; 11(1)
F. Regis, M. Di Mauro, G. I. Russo, D. Urzì, T. Castelli, G. Morgia
In our report, we synthetize the existing 
evidence to treat SRM with cryoablation. 
When choosing CA, renal preservation, 
oncological outcomes, and related complica-
tions should be considered. Thermal ablation 
allows preservation of renal function and 
studies data highlight that renal preserva-
tion is superior when compared to partial or 
radical nephrectomy [8]. Tumors are treated 
in situ without need for isolation and clamp-
ing of the renal hilum, thus contributing to 
preserve renal function outcomes avoiding 
kidney ischemia. Up to now, randomized 
controlled trials aimed at identifying the 
magnitude of impact of ablation on global 
renal function are still lacking.
In 2012, Wehrenberg-Klee et al. examined 
the impact of thermal ablation on kidney 
function in 48 patients with baseline chronic 
kidney disease (CKD). The Authors esti-
mated that percutaneous ablative treatment 
(radiofrequency and CA) did not negatively 
impact on renal function. In fact, the mean 
overall renal function did not change be-
tween baseline, at 1 month and at 1 year 
after treatment [9].
In 2014, Thompson et al. studied onco-
logical outcome among patient treated with 
PN and CA comparing with those treated 
with percutaneous radiofrequency ablation 
for cT1 disease [10]. They concluded that 
in a cohort of 1424 patients with sporadic 
cT1 renal masses, local recurrence-free sur-
vival (LRFS) was similar among the three 
treatments. Instead, metastases-free survival 
(MFS) was significantly better after PN and 
cryoablation when compared with RFA. 
A subgroup of 379 cT1b patients LRFS 
and MFS resulted similar between PN and 
cryoablation.
Atwell et al., in a sample of 115 tumors 
managed with percutaneous cryoablation 
(PCA), reported technical success without 
enhancement after procedure in 97% of cases 
and no evidence of local progression as new 
enhancement or growth of the ablation site 
in 80 tumors that were followed for a mean 
of 13.3 months [11].
of Surgical Complications) and discharged 
from hospital within 12 days. The level of 
serum creatinine was 0.93 mg/dl immedi-
ately before treatment and 1.18 mg/dl after 
treatment.
At last follow up, ten months after sur-
gery, the patient had no recurrence and renal 
function was stable.
dIsCussIon
NSS for patients with sporadic ipsilateral 
renal tumors shows excellent long-term on-
cological outcomes. Krambeck et al. reported 
their experience with multiple renal tumors 
treated with radical nephrectomy or NSS 
and found 90% and 96% cancer specific sur-
vival, respectively. Thus, in the current era of 
expanding indications for NSS, patients with 
multiple renal tumors should be considered 
candidates for nephron-sparing. This is par-
ticularly important, given the higher risk 
of subsequent metachronous lesions in the 
contralateral kidney in these patients [5,6].
In the last decade, long-term data revealed 
safe oncological outcomes in patients treat-
ed for small kidney cancers with nephron-
sparing surgery. More recently, minimally 
invasive modalities for treatment of small 
renal masses (SRM) have been investigated 
as alternative to partial nephrectomy.
Although partial nephrectomy remains 
the gold standard, cryoablation is becom-
ing apparent and in selected patients could 
be a valid alternative. Cryoablation can be 
performed percutaneously in the radiol-
ogy suite, or laparoscopically without the 
need for hilar clamping. Unfortunately, 
only short- and intermediate-term data are 
available, but they seem to be promising, 
especially in patients who are considered 
poor candidates for more involved surgery. 
Numerous clinical trials have been published 
on cryoablation, often involving just a lim-
ited number of patients [7]. Ideally, ablative 
treatment should be compared with partial 
nephrectomy (PN) in a randomized and 
prospective setting.
What should the clinician ask him/herself
 y Which is patient’s renal function in terms of serum creatinine and glomerular filtration rate?
 y How old is the patient?
 y Which are renal masses locations?
 y Which are the enhancement characteristics at CT scan of such lesions?
 y How large are the lesions and are they close to urinary tract?
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for Adverse Events grading system [14]. 
Sprenkle et al. reported complications rate 
of 13% approximately as well [15]. Sidana et 
al., in a sample of 162 patients undergone to 
PCA, LCA, or open CA, reported complica-
tion rates higher, up to 23.5% (complications 
were categorized using the Clavien-Dindo 
system). No independent risk factors, such 
as tumor size or the number of cryoprobes 
used were noted to be associated with in-
creased risk for perinephric hematoma for-
mation [16].
ConClusIons
Thermal ablation is an increasingly used 
treatment option in the management of 
SRMs. The choice should be considered 
in reason of age, preoperative renal insuffi-
ciency, solitary kidneys or multiple renal le-
sions balancing with the risk of preoperative 
complications. However, due to the limited 
experience on cryoablation, larger studies in-
cluding the long-term outcome are needed 
and prospective studies are requisite the bet-
ter to define the role of ablative therapy in 
the treatment of small kidney tumors.
ACknowledgeMents
Written informed consent was obtained 
from the patient for the publication of the 
present case report and accompanying im-
age.
Key points
 y The management of localized renal cell carcinoma has evolved toward minimally invasive 
and nephron-sparing surgery, including cryoablation
 y Although partial nephrectomy remains the gold standard, cryoablation is becoming appar-
ent and in selected patients could be a valid alternative
 y In particular, cryoablation can be performed percutaneously in the radiology suite, or 
laparoscopically without the need for hilar clamping, thus allowing preservation of renal 
function and avoiding the risk for kidney ischemia
 y However, to date, only short- and intermediate-term data are available: larger studies 
including the long-term outcome are needed the better to define the role of ablative therapy 
in the treatment of small kidney tumors
More recently, in EuRECA study, Nielsen 
et al. have reported long-term follow up 
study. They investigated oncological out-
comes and complication rates in patients 
treated with LCA between 2005 and 2015 
[12]. The study has been conducted in a 
large cohort and the Authors concluded that 
LCA demonstrates satisfactory long-term 
oncological outcomes for T1a: in fact, the 
5-/10-year disease free survival (DFS) was 
90.4%/80.0% and 5-/10-year overall survival 
(OS) was 83.2%/64.4%, respectively. The 
secondary aim of the study was to evaluate 
the occurrence of postoperative complica-
tions within 30 days of treatment. Postop-
erative complications were defined according 
to the Clavien-Dindo classification system 
[13]. Any complication having grade ≥ IIIa 
was defined as severe. They reported rate of 
postoperative complication of 16.6%, with 
severe complications (grade ≥ III) of 3.2%.
Therefore, although LCA is considered a 
minimally invasive technique, risk of com-
plications should be considered. The most 
common complications found in literature 
are hemorrhage, perinephric hematoma, and 
urine leak. Other complications reported 
are flank pain, perinephric hematoma, and 
cardiovascular complications, including ar-
rhythmia, deep venous thrombosis, hypo- 
and hypertension and cases of myocardial 
infarction.
Kapoor et al. in their review reported rate 
of complications of 13% when evaluated us-
ing the Clavien-Dindo system and 7% when 
using the Common Terminology Criteria 
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